JP2013528656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528656A5 JP2013528656A5 JP2013515497A JP2013515497A JP2013528656A5 JP 2013528656 A5 JP2013528656 A5 JP 2013528656A5 JP 2013515497 A JP2013515497 A JP 2013515497A JP 2013515497 A JP2013515497 A JP 2013515497A JP 2013528656 A5 JP2013528656 A5 JP 2013528656A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- disease
- chemokine
- receptor activity
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 102000009410 Chemokine receptor Human genes 0.000 claims 5
- 108050000299 Chemokine receptor Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 208000007353 Hip Osteoarthritis Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 2
- 102000004500 CCR1 Receptors Human genes 0.000 claims 2
- 108010017319 CCR1 Receptors Proteins 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010023230 Joint stiffness Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001088 anti-asthma Effects 0.000 claims 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 239000000924 antiasthmatic agent Substances 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 2
- 229960004963 mesalazine Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000003589 nefrotoxic effect Effects 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 231100000381 nephrotoxic Toxicity 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 1
- 229940123038 Integrin antagonist Drugs 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35522510P | 2010-06-16 | 2010-06-16 | |
| US61/355,225 | 2010-06-16 | ||
| PCT/US2011/040605 WO2011159852A1 (en) | 2010-06-16 | 2011-06-16 | Piperidinyl compound as a modulator of chemokine receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528656A JP2013528656A (ja) | 2013-07-11 |
| JP2013528656A5 true JP2013528656A5 (enExample) | 2014-07-31 |
| JP5795797B2 JP5795797B2 (ja) | 2015-10-14 |
Family
ID=44278764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515497A Expired - Fee Related JP5795797B2 (ja) | 2010-06-16 | 2011-06-16 | ケモカイン受容体活性の調整薬としてのピペリジニル化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8642622B2 (enExample) |
| EP (1) | EP2582670B1 (enExample) |
| JP (1) | JP5795797B2 (enExample) |
| KR (1) | KR20130032357A (enExample) |
| CN (1) | CN103068800B (enExample) |
| AR (1) | AR081943A1 (enExample) |
| AU (1) | AU2011268373B2 (enExample) |
| BR (1) | BR112012031768A2 (enExample) |
| CL (1) | CL2012003521A1 (enExample) |
| CO (1) | CO6650362A2 (enExample) |
| EA (1) | EA022395B1 (enExample) |
| IL (1) | IL223368A0 (enExample) |
| MA (1) | MA34377B1 (enExample) |
| MX (1) | MX2012014068A (enExample) |
| NZ (1) | NZ605741A (enExample) |
| SG (1) | SG186064A1 (enExample) |
| TN (1) | TN2012000581A1 (enExample) |
| TW (1) | TW201206435A (enExample) |
| WO (1) | WO2011159852A1 (enExample) |
| ZA (1) | ZA201300380B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011044197A1 (en) * | 2009-10-07 | 2011-04-14 | Bristol-Myers Squibb Company | Spirocyclic compounds as modulators of chemokine receptor activity |
| US9018374B2 (en) | 2010-06-16 | 2015-04-28 | Takeda Pharmaceutical Company Limited | Crystal of amide compound |
| DK3297438T3 (da) | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| ES2992410T3 (es) | 2016-09-16 | 2024-12-12 | Lighthouse Pharmaceuticals Inc | Inhibidores cetónicos de la lisina gingipaína |
| EP3375778A1 (en) * | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| CA3293051A1 (en) | 2017-09-25 | 2026-03-02 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| KR102037494B1 (ko) | 2017-12-11 | 2019-10-28 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
| CN112105353B (zh) | 2018-01-08 | 2024-04-19 | 凯莫森特里克斯股份有限公司 | Ccr2拮抗剂治疗实体瘤的方法 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| AU2023376006A1 (en) | 2022-11-09 | 2025-03-13 | Boehringer Ingelheim International Gmbh | Cyclic pyridine derivatives as cgas inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
| DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5777112A (en) | 1994-06-13 | 1998-07-07 | Merck & Co., Inc | Piperazine compounds promote release of growth hormone |
| CN1195343A (zh) | 1995-07-13 | 1998-10-07 | 千寿制药株式会社 | 哌啶衍生物及其用途 |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| SK285631B6 (sk) | 1996-09-10 | 2007-05-03 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie |
| AU4722197A (en) | 1996-10-22 | 1998-05-15 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
| US5847148A (en) | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| PL343770A1 (en) | 1998-04-16 | 2001-09-10 | Texas Biotechnology Corp | N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| WO2001098268A2 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
| ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
| CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| DE10124041A1 (de) | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| PE20030703A1 (es) | 2001-09-06 | 2003-08-21 | Schering Corp | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 |
| US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| GB0224917D0 (en) | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| WO2004042351A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| RU2006100190A (ru) | 2003-06-13 | 2006-08-10 | Шеринг Акциенгезельшафт (De) | Производные хинолиламида в качестве антагонистов ccr-5 |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| DE10358539A1 (de) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| US7723360B2 (en) | 2004-08-06 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Alkyl-and piperidine-substituted benzimidazole derivatives |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| CN101600691A (zh) * | 2006-01-27 | 2009-12-09 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的哌啶基衍生物 |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| WO2009015166A1 (en) | 2007-07-24 | 2009-01-29 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| CN101808991A (zh) | 2007-07-24 | 2010-08-18 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的哌啶基衍生物 |
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
-
2011
- 2011-06-15 US US13/160,944 patent/US8642622B2/en active Active
- 2011-06-16 EP EP11728134.5A patent/EP2582670B1/en not_active Not-in-force
- 2011-06-16 AR ARP110102087A patent/AR081943A1/es unknown
- 2011-06-16 KR KR1020137001026A patent/KR20130032357A/ko not_active Withdrawn
- 2011-06-16 BR BR112012031768A patent/BR112012031768A2/pt not_active IP Right Cessation
- 2011-06-16 SG SG2012085353A patent/SG186064A1/en unknown
- 2011-06-16 WO PCT/US2011/040605 patent/WO2011159852A1/en not_active Ceased
- 2011-06-16 TW TW100121094A patent/TW201206435A/zh unknown
- 2011-06-16 MX MX2012014068A patent/MX2012014068A/es active IP Right Grant
- 2011-06-16 JP JP2013515497A patent/JP5795797B2/ja not_active Expired - Fee Related
- 2011-06-16 NZ NZ605741A patent/NZ605741A/en not_active IP Right Cessation
- 2011-06-16 CN CN201180039590.3A patent/CN103068800B/zh not_active Expired - Fee Related
- 2011-06-16 MA MA35558A patent/MA34377B1/fr unknown
- 2011-06-16 AU AU2011268373A patent/AU2011268373B2/en not_active Ceased
- 2011-06-16 EA EA201270790A patent/EA022395B1/ru not_active IP Right Cessation
-
2012
- 2012-11-29 IL IL223368A patent/IL223368A0/en unknown
- 2012-12-07 TN TNP2012000581A patent/TN2012000581A1/en unknown
- 2012-12-12 CL CL2012003521A patent/CL2012003521A1/es unknown
-
2013
- 2013-01-04 CO CO13001893A patent/CO6650362A2/es active IP Right Grant
- 2013-01-15 ZA ZA2013/00380A patent/ZA201300380B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528656A5 (enExample) | ||
| JP7083398B2 (ja) | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 | |
| JP2018529762A5 (enExample) | ||
| JP2020055813A5 (enExample) | ||
| JP2011526293A5 (enExample) | ||
| JP2017512186A5 (enExample) | ||
| JP2017504651A5 (enExample) | ||
| JP2017504650A5 (enExample) | ||
| HRP20230377T1 (hr) | Inhibitori mutacije kras g12c | |
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| BR112020006780A2 (pt) | moduladores do estimulador de genes do interferon (sting) | |
| JP2011528658A5 (enExample) | ||
| RU2015111259A (ru) | Способы проведения терапии пирфенидоном | |
| JP2012525393A5 (enExample) | ||
| JP2015503527A5 (enExample) | ||
| JP2014526492A5 (enExample) | ||
| JPH11335375A (ja) | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 | |
| FI2744810T4 (fi) | Tenofoviirialafenamidihemifumaraatti | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| CN107428693A (zh) | 用于hiv治疗的异喹啉化合物 | |
| WO2010077740A2 (en) | Novel antiviral compounds, compositions, and methods of use | |
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2017528503A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| TW201040178A (en) | Indolizine derivative and use thereof for medical purposes |